Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 5,521 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Interventions: Rev-56 for Inhalation, Placebo: Normal saline; Combination Product · Drug
Lead sponsor: Revagenix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more

Conditions: Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York

Conditions: Menopause, Hot Flashes, Mood
Interventions: Shatavari extract, Shatavari + Ashwagandha extract, Placebo; Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: COPD
Interventions: Arformoterol tartrate inhalation solution, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 31
States / cities: Encinitas, California • Long Beach, California • Brandon, Florida + 28 more

Conditions: HER2 Positive Breast Cancer
Interventions: tucatinib, capecitabine, trastuzumab, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more

Conditions: Crohn's Disease
Interventions: Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obsessive-Compulsive Disorder
Interventions: Troriluzole, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 57
States / cities: Chandler, Arizona • Little Rock, Arkansas • Garden Grove, California + 52 more

Conditions: Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions: atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-traumatic Stress Disorder, Post Traumatic Stress Disorder, Stress Disorder, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions: 60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 14 more

Conditions: Gastrointestinal Health, Immune Health, Cardiovascular Health, Digestive Health
Interventions: Bacillus subtilis BS50 spore preparation, Maltodextrin; Dietary Supplement
Lead sponsor: BIO-CAT Microbials, LLC; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Atrial Fibrillation, Vascular Risk
Interventions: clopidogrel (SR25990C), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 7,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Rheumatoid Arthritis
Interventions: GLPG0634, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more

Conditions: Abdominal Aortic Aneurysm
Interventions: Telmisartan, Placebo; Drug
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 50 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Nonalcoholic Fatty Liver Disease
Interventions: Saroglitazar Magnesium 4 mg, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide, Matching Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 71
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more

Conditions: Depressive Disorder, Major
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 47
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin, Pioglitazone, Metformin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 104
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more

Conditions: Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions: Aspirin, Clopidogrel, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infection
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Healthy
Interventions: LY3549492, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Scottsdale, Arizona • Covina, California • Northridge, California + 8 more

Conditions: Myelofibrosis
Interventions: Selinexor, Placebo, Ruxolitinib; Drug · Other
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 36
States / cities: Birmingham, Alabama • Beverly Hills, California • Duarte, California + 31 more

Search by objective public record fields.

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

ARREST PAD (Peripheral Arterial Disease)

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Effect of Bacillus Subtilis BS50 Supplementation on Gastrointestinal Symptoms in Healthy Adults

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

A Clinical Trial of Antiplatelets in Psoriasis

Clinical Trial to Reduce Drinking in Women With HIV

A Study of LY3549492 in Healthy Weight Adult Participants

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis